|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumor homogeneity between primary and metastatic sites for BRAF status in metastatic melanoma determined by immunohistochemical and molecular testing.
|
23976959 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study.
|
23735514 |
2013 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Compared with vemurafenib, dabrafenib is a more recent BRAF inhibitor approved by the Food and Drug Administration in May 2013 for metastatic melanoma; fewer data are available in the current literature regarding cutaneous toxicity.
|
27624900 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although cAMP elevation did not alter the sensitivity of metastatic melanoma cells to BRAF(V600E) and MEK inhibitors, the EPAC-RAP1 axis appears to contribute to resistance to MAPK pathway inhibition.
|
28851815 |
2017 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This phase Ib study (ClinicalTrials.gov, number NCT01656642 ) evaluated the safety and anti-tumor activity of combining atezolizumab (anti-PD-L1) with vemurafenib (BRAF inhibitor), or cobimetinib (MEK inhibitor) + vemurafenib, in patients with BRAF<sup>V600</sup>-mutated metastatic melanoma.
|
31171876 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We report a patient with BRAF mutant metastatic melanoma treated with the BRAFi/MEKi combination therapy who developed an acneiform eruption after treatment discontinuation rather than during active therapy.
|
24922191 |
2014 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We present the case of a 67 year old Caucasian male that was initially treated with BRAF inhibitors followed by anti-CTLA4 and then anti-PD1 immunotherapy for metastatic melanoma but later developed colorectal cancer.
|
31727009 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We describe peripheral blood smear, bone marrow morphology, histopathology, immunohistochemistry, including BRAF V600E, and molecular testing results of patients with metastatic melanoma to the bone marrow.
|
31112348 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Vemurafenib is a tyrosine kinase inhibitor of BRAF that prolongs survival in patients with BRAF V600-mutant metastatic melanoma.
|
24946815 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this paper is to make evidence-based recommendations to facilitate the implementation of BRAF mutation testing and targeted therapy in patients with metastatic melanoma in the U.K.
|
23360189 |
2013 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A total of 48 patients (24 male, 24 female) with BRAF-mutated metastatic melanoma received dabrafenib and trametinib; median age was 48 years (range 23-75).
|
27470608 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Taken together, our findings support the concept that triple therapy directed against BRAF/MEK/ErbB3 may be able to provide durable control of BRAF mutated metastatic melanoma.
|
26208478 |
2015 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Tissue samples obtained from EBUS TBNA are adequate to diagnose metastatic melanoma in hilar and mediastinal lymph nodes and to detect the presence or absence of mutations in the BRAF gene.
|
22617000 |
2012 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Efficacy and safety of dabrafenib-trametinib in the treatment of unresectable advanced/metastatic melanoma with BRAF-V600 mutation: A systematic review and network meta-analysis.
|
31664762 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The interval from diagnosis of first-ever melanoma to distant metastasis was not significantly different between BRAF-mutant and BRAF wild-type patients; however, the median survival of patients with newly diagnosed metastatic melanoma was 5.7 months for BRAF-mutant patients not treated with a BRAF inhibitor, 8.5 months for BRAF wild-type patients, and not reached for BRAF-mutant patients treated with a BRAF inhibitor.
|
21343559 |
2011 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Conclusion This 5-year analysis represents the longest follow-up to date with BRAF + MEK inhibitor combination therapy in BRAF V600-mutant MM.
|
28991513 |
2018 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A phase I, randomized, open-label study of the multiple-dose pharmacokinetics of vemurafenib in patients with BRAF V600E mutation-positive metastatic melanoma.
|
24178368 |
2014 |
|
Metastatic melanoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The combination of BRAF and MEK inhibitors is a standard therapeutic option for patients with metastatic melanoma with BRAF-mutated tumors.
|
30383722 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In contrast to metastatic melanoma, BRAF inhibition alone or in combination with mitogen-activated protein kinase kinase (MEK) inhibitors has shown little utility in the treatment of BRAF V600E-mutant mCRC.
|
31840683 |
2019 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
For the treatment of metastatic melanoma, Vemurafenib is recommended for patients with BRAF V600 activating mutations.
|
24969466 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
|
27151331 |
2016 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Control of BRAF(V600E) metastatic melanoma by BRAF inhibitor (BRAF-I) is limited by intrinsic and acquired resistance.
|
24732172 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We assessed vemurafenib in patients with advanced metastatic melanoma with BRAF(V600) mutations who had few treatment options.
|
24582505 |
2014 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The development of BRAF kinase inhibitors as targeted treatments for patients with BRAF-mutant tumours contributed profoundly to an improved overall survival of patients with metastatic melanoma.
|
28408301 |
2017 |
|
Metastatic melanoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Phase 1 and 2 clinical trials of the BRAF kinase inhibitor vemurafenib (PLX4032) have shown response rates of more than 50% in patients with metastatic melanoma with the BRAF V600E mutation.
|
21639808 |
2011 |